Net Loss Per Share Attributable to Common Stockholders (Tables)

3 Months Ended

Mar. 31, 2022

Earnings Per Share [Abstract]

Weighted-Average Common Stock Equivalents Excluded from Calculation of Diluted Net Loss Per Share as They Had Anti-Dilutive Effect

The following weighted-average common stock equivalents were excluded from the calculation of diluted net loss per share for the periods presented as they had an anti-dilutive effect:

	Three Months Ended March 31,
	2022		2021
Options to purchase common stock		1,153,444		826,748
Contingently issuable common stock prior to exchange of    Vaccinex Products, LP units		-		1,147,259
Contingently issuable common stock prior to exchange of    VX3 units		-		1,309,028